Opsens Inc. (OPS) EPS Estimated At $0.00; Intec Pharma Limited Ord (NTEC) SI Decreased By 72.73%

June 23, 2017 - By Kurt Siggers

Analysts expect Opsens Inc. (TSE:OPS) to report $0.00 EPS on July, 4. The stock decreased 2.34% or $0.03 on June 22, reaching $1.25. About 51,075 shares traded or 56.53% up from the average. Opsens Inc. (TSE:OPS) has 0.00% since June 23, 2016 and is . It has underperformed by 16.70% the S&P500.

Intec Pharma Limited Ord (NASDAQ:NTEC) had a decrease of 72.73% in short interest. NTEC’s SI was 900 shares in June as released by FINRA. Its down 72.73% from 3,300 shares previously. With 5,100 avg volume, 0 days are for Intec Pharma Limited Ord (NASDAQ:NTEC)’s short sellers to cover NTEC’s short positions. The SI to Intec Pharma Limited Ord’s float is 0.01%. The stock increased 0.94% or $0.05 on June 22, reaching $5.35. About shares traded. Intec Pharma Ltd (NASDAQ:NTEC) has risen 51.00% since June 23, 2016 and is uptrending. It has outperformed by 34.30% the S&P500.

Among 3 analysts covering Intec Pharma (NASDAQ:NTEC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 3 analyst reports since September 11, 2015 according to SRatingsIntel. On Friday, September 11 the stock rating was initiated by TH Capital with “Buy”. The firm earned “Buy” rating on Wednesday, September 16 by Maxim Group. Roth Capital initiated Intec Pharma Ltd (NASDAQ:NTEC) rating on Friday, September 11. Roth Capital has “Buy” rating and $9.50 target.

Intec Pharma Ltd is an Israel-based drug development company. The company has market cap of $72.12 million. It is a development stage biopharmaceutical firm that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. It currently has negative earnings. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Opsens Inc. provides fiber optic sensing technology. The company has market cap of $104.07 million. The Firm operates through two divisions: Medical and Industrial. It currently has negative earnings. In Medical segment, the Company focuses on the measure of Fractional Flow Reserve in interventional cardiology.